Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Chronic Myeloid Leukemia (CML)

 

LBH589 with Imatinib Mesylate for CML (2412)
A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR

Investigator: Vivian Oehler, MD;   Conditions: Chronic Myeloid Leukemia (CML);    Status: Closed;   Study ID: NCT00686218

Dasatinib Versus Imatinib for Chronic Phase Chronic Myeloid Leukemia
An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib

Investigator: Vivian G. Oehler, MD;   Conditions: Chronic Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01593254